Sunny Xie
About Sunny Xie
Sunny Xie serves as the Vice President of Biometrics and R&D Systems at Nektar Therapeutics, where he has worked since 2015. He has extensive experience in clinical applications, statistical analysis, and regulatory affairs, having held senior roles at several prominent pharmaceutical companies.
Current Role at Nektar Therapeutics
Sunny Xie currently serves as the Vice President of Biometrics and R&D Systems at Nektar Therapeutics. In this role, which he has held since 2015, he is responsible for overseeing biometrics and research and development systems. His leadership has been instrumental in advancing the company's initiatives in immuno-oncology, particularly in the development of programs starting from first-in-human studies.
Previous Experience at Shire
Prior to his current position, Sunny Xie worked at Shire in various capacities. He served as Senior Director of Clinical Process Optimization in Clinical Development Operations and Biometrics from 2010 to 2013. He also held the role of Senior Director of Clinical Applications, Support, and Training for one year in 2013. His tenure at Shire contributed to his expertise in clinical processes and operational efficiency.
Experience at Eli Lilly and Company
Sunny Xie worked at Eli Lilly and Company from 2000 to 2005 as a Group Leader and Statistical Analyst within the Lilly Icos Joint Venture. His five years at Eli Lilly provided him with a strong foundation in statistical analysis and leadership in clinical research, which has been beneficial throughout his career.
Educational Background
Sunny Xie holds a Bachelor of Science degree in Design from Shandong University. He further advanced his education by obtaining a Master of Science degree in Statistics from Sam Houston State University. His academic background has equipped him with the necessary skills for his roles in biometrics and statistical programming.
Achievements in Statistical Programming
Throughout his career, Sunny Xie has demonstrated strategic leadership in building teams and processes. He established a robust Biostats and Statistical Programming team from the ground up at Nektar Therapeutics. Additionally, he played a key role in the FDA submission process for a pain program, showcasing his expertise in regulatory affairs and clinical development.